Several isolated dimorphisms recur in many HLA class II alleles, but it is not clear whether they merely influence the binding of peptides locally or have more general effects on their recognition by T cells. For example, interchanges in HLA-DRβ include 86 Gly ↔ Val and 57 Asp ↔ Ser at either end of its α helix, and 71 Arg ↔ Lys in the middle. In DR4, the existence of six subtypes differing by single substitutions at these sites enabled us to assess their functional effects-both in isolation and in their natural context-on peptide presentation to a specific T cell clone with unusually broad crossrestrictions. Unexpectedly, the restriction imposed by 86 Val was much more severe in the context of 71 Arg than 71 Lys, but was also more readily overcome by reducing the bulk of the 'p1' peptide 'anchor' residue ( 149 Trp → Phe). Moreover, when there was also a distant 57 Asp→Ser substitution, compensating similarly for 86 Val proved much more difficult. Thus 86 Val and 57 Ser in combination had far more drastic effects on peptide presentation than they did separately, when peptide binding was also largely unchanged. These and other interactions with position 71 together provide strong evidence that the configuration of the peptide-DR4 complex is critical for T cell recognition, which could be affected by subtle conformational influences on the p1-9 core of the peptide or on the α helix of DR4β (between positions 86 and 57). Ideally, therefore, the effects of individual class II substitutions should be considered in their natural context rather than in isolation.
Introduction
Although MHC molecules are highly polymorphic, the differences between alleles of HLA-DR are very localized (1)-often to positions in the β chain that contact the peptides in their antigen-binding grooves (2, 3) . There are several hypervariable regions where alternative 'cassettes' of sequence occur, such as the 67 L-70 QR motif in HLA-DR1 and many subtypes of DR4 versus 67 I-70 DE in DR4;Dw10 and other alleles (Table 1) . However, at other isolated positions, the variety of amino acids is very limited; at one end of the α Correspondence to: N. Willcox Transmitting editor: E. Simpson Received 6 November 1998, accepted 3 February 1999 helix, for example, 57 Asp is common, but some DR or DQ alleles have 57 Ser, Val or Ala instead (1) . Likewise, in the middle at position 71, there is an isolated 71 Arg ↔ Lys interchange in some subtypes of DR4 (Table 1 ). Located at the far end of the helix is the extreme case of DRβ position 86, where the only known alternatives are Val and Gly-which are often the only differences between the subtypes of DR4 (Table 1) , DR15, DR13 or DR52 (1) . The crystal structures (2, 3) show a hydrophobic 'pocket' here that accommodates b These lines were used as a source of DR molecules for peptide binding, but, for presentation by Dw4.2 to T cells, the Boleth line was used instead. the major 'p1 anchor' residue of many peptides; moreover, by restricting the access of bulkier residues to it, this 86 Val can have radical overall effects on peptide binding and recognition (2, 3, 6, 8, 9) .
Such interchanges must surely cause subtle local adjustments to individual side-chain-binding pockets. In addition, however, at pivotal sites such as 57, 71 and 86, they might have more general effects on the binding properties of the whole groove or on the conformation of the bound peptides. Since the latter are not easily detected, they have been studied much less. In either case, the wide recurrence of these dimorphisms suggests that they have been selected in evolution to increase the repertoire of epitopes and pathogens that can be recognized. For instance, in the Gambia, DR1302 apparently confers some protection against severe malarial anemia, unlike DR1301 which differs only by having 86 Val instead of Gly (10) .
Particularly intriguing examples are seen in HLA-DR4, where the naturally occurring Dw4, Dw13 and Dw15 subtypes each differ from Dw14 by a single residue, and Dw10 by only three; each of them shows the 86 Gly/Val dimorphism too (Table 1) . For clarity in this report, the subtypes of DR4 with 86 Val are denoted 'Dw4.1', 'Dw10.1', etc., and those with 86 Gly 'Dw4.2', 'Dw10.2', etc. (Table 1) . Moreover, these differences must hold important clues for immunopathologic responses. For example, severe rheumatoid arthritis associates strongly with HLA-DR4, but only with its Dw4, Dw14 and Dw15 subtypes (11) (12) (13) (14) . That could reflect differences in peptide binding, which have been studied extensively (8, 9, (15) (16) (17) (18) (19) (20) (21) , or in presentation to specific T cells, which often prove to be much greater when they are tested (6, 8, 9, 14, (19) (20) (21) (22) . In most reports (e.g. 8, 21) , substitutions were tested in isolation by sitedirected mutagenesis and it was tacitly assumed that their effects could be generally extrapolated to other alleles/subtypes, regardless of the precise context. We were able to test that by measuring peptide presentation to a T cell clone (PM-A1) that shows unusual cross-restrictions to several DR4 subtypes (14) . This clone, originally selected from the thymus of a DR4;Dw14.2 ϩ myasthenia gravis (MG) patient, is highly sensitive to a natural α149-158 epitope in the human acetylcholine receptor (AChR) α subunit (6, 14) . When we used it to study these dimorphisms in their natural setting (in the panel of DR4 subtypes listed in Table 1 ), we unexpectedly observed striking interactions between them, which we summarize here.
Methods

Antigens
Peptides were synthesized by standard Fmoc chemistry (23) . The N-terminal biotinylated myelin basic protein (MBP) peptide Tyr84-102 was purified by reverse-phase HPLC, and checked by HPLC and mass spectroscopy; its sequence is YDENPVVHFFKNIVTPRTPP. Other sequences are given in the figures.
Peptide-binding assays
Cell pellets from 40 l spinner flasks were solubilized in 0.5% Triton X-100 and HLA-DR molecules were purified by affinity chromatography with the mAb L243: they were incubated overnight (at 50 nM) at 37°C in pH 5.5 citrate buffer with 1000 nM biotinylated MBP peptide plus 1-100,000 nM of unlabeled competitor in 0.2% NP-40, 0.01% NaN 3 and a protease inhibitor mix (24) . The HLA-DR peptide complexes were added to 96-well plates precoated with mAb L243 and incubated for 2 h at 4°C. Plates were subsequently washed with 0.1% Tween 20 in Tris-buffered saline (0.5 M Tris, 1.5 M NaCl, pH 7.5) to remove unbound material, incubated with 100 ng/ml europium-streptavidin (Wallac, Turku, Finland) for 90 min and washed again in this buffer. To detect the europium fluorescence, DELFIA enhancement solution (Wallac) was added and plates were analyzed in a Wallac 1234 DELFIA research fluorometer (Wallac). Triplicate samples for each unlabeled AChR α peptide were tested at each concentration and the IC 50 (the concentration of unlabeled peptide required for 50% inhibition of the binding of the MBP peptide) was determined by four-parameter fit analysis with the software program SOFTmax Pro.
T cell proliferation assay
We used the Epstein-Barr virus-transformed B cell lines listed in Table 1 as antigen-presenting cells (APC). They were maintained in 10% FCS in RPMI 1640 (Gibco, Paisley, UK); before use, they were pre-treated with mitomycin C (Sigma, Poole, UK) at 50 µg/ml for 1 h and thoroughly washed. They were then pulsed with varying peptide concentrations at 8ϫ10 6 cells/ml at 37°C in 5% A ϩ human serum in RPMI medium; the standard time was 90-120 min, but ranged up to 5-12 h in some experiments. The cells were then washed thoroughly before co-culture (at 10 5 cells/well in RPMI/5% serum) with well rested pre-washed PM-A responder T cells (2.5ϫ10 4 /well) in 200 µl round-bottomed microtiter plates (Nunclon, Roskilde, Denmark). In some experiments, antigens were added as a continuous stimulus rather than a pre-pulse. After 72 h, 1 µCi of [ 3 H-methyl]thymidine (Amersham, Little Chalfont, UK) was added to each well; 18 h later, they were harvested and counted on a Betaplate flat bed liquid scintillation counter (Wallac). The PC 50 was the peptide molarity required for half-maximal T cell stimulation; each peptide-DR4 subtype combination was tested at least twice to determine this value.
The responder T cells were the PM-A line (6) and its PM-A1 clone (25) ; since their behavior and TCR sequences are identical, they were used interchangeably. They were maintained by fortnightly re-stimulation with recombinant AChR α subunit plus irradiated DR4;Dw4.2 ϩ irradiated peripheral blood lymphocytes and expansion with highly purified IL-2 (Biotest, Solihull, UK) (6). 
Results
Experimental approach
We tested peptide presentation to PM-A T cells by 10 different HLA-DR4 subtypes (Table 1) ; in most experiments, the APC were preincubated with peptide (and then thoroughly washed), in order to pre-load their class II molecules and assay for 'functional binding' as well as to prevent the strongly class II ϩ responder T cells from subsequently presenting these peptides to each other.
The presenting HLA-DR4 subtypes and the p1 anchor residue
As is typical with T cells from Dw14.2 ϩ donors (14), and is illustrated in Fig. 1(a) , the PM-A T cell responds very well to its natural epitope when presented by Dw14.2 and Dw15.2, whereas much higher doses are required with Dw13.2 and there is no detectable response with Dw13.1 or Dw10 (6, 14) . Unusually, however, presentation is also consistently maximal by Dw4.2 (Fig. 1a) ; even though its 71 Arg→Lys substitution completely prevents presentation to three other Dw14.2-restricted T cells (14) , this is no obstacle to PM-A.
The natural epitope is not presented detectably by Dw14.1 (6,14) (Fig. 1a) , which differs only by 86 Gly→Val (1,6). As illustrated in Fig. 1, 149 Trp is clearly the p1 anchor; merely replacing it with a less bulky 149 Phe completely and consistently overcomes this restriction in Dw14.1 ( Fig. 1b) (14) . However, when we tried to extend this finding to Dw4.1 and Dw15.1, we noted two surprising contrasts.
(i) In Dw4.1 (which differs from Dw14.1 by 71 Arg→Lys), this 86 Val restriction had much milder effects, despite a 149 Trp at peptide p1. Though 86 Val still prevented presentation of shorter peptides (e.g. p143-156) (14) , that was overcome merely with a higher dose of the more potent p144-163 (ii) For presentation to PM-A T cells by the indicated DR4 subtype, expressed as the PC 50 values (i.e. after pre-pulsing the APC for 2-3 h). Every peptide-subtype combination was tested at least twice. Shown above is the residue in the parent sequence that was substituted by the indicated amino acid. Note that the scales for PC 50 (on the left) and for IC 50 (on the right) are not always the same. Both Dw13.2 and Dw15.1 are even less potent than appears, as they were tested here after prolonged pulsing (6-9 h ), because responses were much weaker after 2-3 h. None of these peptides was presented detectably by Dw10.2, which may bind more weakly. With Dw13.2, the negative result with the 152 Asp→Ala substituent argues against simple repulsion by the 74 Glu in this DRβ, as also noted elsewhere (26) . (Fig. 1a) . Moreover, this minor 'insensitivity' was not altered by substituting a 149 Phe at p1 (Fig. 1b) .
(ii) There was a stark contrast with Dw15, which has a distinctive 57 Asp→Ser replacement. Whereas Dw15.2 clearly presents peptides very efficiently ( Fig. 1 ; see also Fig. 2 ), the corresponding 86 Val restriction in Dw15.1 was only overcome with great difficulty. That required prolonged pulses at high molarities of variants of (a) the shorter p146-158 sequencetruncated at p10-which were presented remarkably well by Dw15.1 in view of their weakness in other subtypes (Table 2) or of (b) the very potent p145-163 ( 149 Phe) sequence (see Fig. 2 ). Thus this restriction was much more severe in the context of both 86 Val and 57 Ser than of either alone.
To investigate further these strikingly different effects of the same 86 Gly ↔ Val dimorphism in the context of the 71 Arg → Lys and the 57 Asp → Ser substitutions, we next identified critical residues in the peptide.
Critical residues in the epitope
We systematically replaced each residue from 146-160 (in turn) with Ala, apart from 157 Ala, which was changed to Lys or Tyr instead. To adapt these analogues to subtypes with 86 Val, we concomitantly replaced 149 Trp with Phe (throughout) at p1 in the 145-163 'parent' sequence and we tested their presentation to PM-A as above (Fig. 2) . A diagram of a DR4-peptide complex is shown in Fig. 3 . For peptide binding. Firstly, we confirmed the anchoring roles of p1 and p9, and established that nearly all of the other variants bound similarly well to isolated Dw4.2 molecules (Fig. 2a) . Thus, the IC 50 was~20-fold higher for the 149 Phe → Ala variant at p1; this weak but significant binding reflects contributions from secondary anchor residues (15, 16, 18) . The IC 50 was also higher for a Lys substituent for the 157 Ala at p9 that is known to be favorable for DR4 (3, 15, 16, 18) . We could assay binding to Dw14.1 molecules too, as there are B cell lines homozygous for Dw14.1, though not for the autologous Dw14.2. In general, this required 5-to 10-fold more of most analogues than with Dw4.2 (note the different scales in Fig. 2a  and b) , and higher concentrations still of the p6, p7 and p9 variants (Fig. 2b) . Also, binding to Dw14.1 was undetectable with the 149 Tyr substituent at p1; with 149 Ala, however, it was slightly stronger than with Dw4.2.
For peptide presentation to PM-A T cells. The data on presentation of these variants highlight several general points (Fig. 2) . Firstly, they show that the binding register was the same in each subtype, and confirm the key anchoring roles of the p1 and p9 residues discussed above. Secondly, as expected from the crystal structure of the DR-peptide complex (2,3), the primary TCR contact residue is 153 Gly at p5; neither the conservative 153 Ala nor 153 Ser substituents were recognized detectably in any subtype, despite binding well to Dw4.2 and Dw14.1 ( Fig. 2a and b) . Secondary TCR contact sites include 150 Thr at p2, especially 151 Tyr at p3, and also 156 Val at p8 in Dw4.2 (as shown by weaker presentation despite average binding). However, 147 Gly and 148 Thr appear less important here than in DR52a and DR3 (27) . Indeed, in DR4, the substitutions at either end had much less effect than those in the core of the epitope.
In addition, these data provide further evidence for the interactions between positions 86 and 71 or 57 noted above (i) and (ii), and also add another example (iii).
(i) The Arg ↔ Lys dimorphism at position 71. We noted four major effects of this dimorphism. Firstly, when there was a 71 Lys (in Dw4.1), the 86 Val had no effect on presentation of the 149 Tyr substituent (Fig. 2a) , whereas, in the context of 71 Arg, it caused all-or-nothing differences, i.e. between both Dw14.2/14.1 (Fig. 2b) and Dw15.2/15.1 (Fig. 2c) . Secondly, with all of the other analogues, Dw4.2 and Dw4.1 gave almost identical PC 50 values (Fig. 2a) , whereas there were significant discrepancies between Dw14.2 and Dw14.1, especially at p6-9 (cf. the open symbols in Fig. 2b ). Thirdly, with Dw4.2, the molarities required for the stimulatory analogues were close to their IC 50 values (within a factor of 3, Fig. 2a) . In sharp contrast, with Dw14.1, presentation was, in general, 5-to 10-fold more efficient, even though the binding was 5-to 10-fold weaker (note the different scales in Fig. 2a and  b) . Thus, many PC 50 s were 30-1000 times lower than the corresponding IC 50 s, so that functional binding was disproportionately potent in the context of the autologous 71 Arg. Fourthly, these differences from Dw4 were most extreme for the substituents for the core residues, especially p2-4, p6 and p8, several of which are secondary TCR contact sites (2,3); these variants were not recognized detectably in the context of 71 Lys, even though they bound well (Fig. 2a) , whereas, with Dw14.1, presentation generally correlated much better with peptide binding (despite requiring lower molarities). Moreover, the overall profile for presentation was broadly similar for the three main subtypes with 71 Arg, and differed starkly from those with 71 Lys (cf. Fig. 2b and c with a; open symbols).
(ii) Position 57. Despite this very similar functional binding by Dw14.1, Dw14.2 and Dw15.2, presentation by Dw15.1 was Ͼ100-fold less efficient for almost all the peptides tested. The responses we found again depended not only on high molarities but also on a prolonged peptide pulse (9 h; Fig. 2  legend) . Relatively, they were stronger to the Ala substituent at p4 and also to those at p10-12 that reduce the C terminal bulk; in general, they correlated with those with Dw15.2 (Fig. 2d) .
Thus the 86 Val and 57 Ser substitutions evidently had far more drastic effects in combination (in Dw15.1) than they did separately (cf. Dw14.1 and Dw15.2 with Dw14.2).
(iii) Notably, too, the analogues for p10-12 were presented by Dw14.1 at 10 times lower molarities than by Dw14.2. Since these subtypes differ only at position 86 near the far end of the peptide, this is another unexpected and remote interaction.
Discussion
This study on peptide presentation to a specific T cell clone has yielded three novel groups of findings.
(i) The major effects of the 86 Gly→Val substitution in HLA-DRβ depend greatly on the context, i.e. both on the particular peptide and on the exact DR4 subtype. Only in Dw14.1 were they easily overcome with a smaller peptide anchor residue at p1. (ii) Even for an unusual T cell that tolerates both 71 Lys and 71 Arg, this interchange still radically influences not only the effects of 86 Val but also the recognition of peptide residues as far apart as p2 and p11.
(iii) A concomitant 57 Asp→Ser substitution near the peptide's C-terminus also greatly reduced our ability to overcome the 86 Val restriction (in Dw15.1) with a smaller p1 anchor near the N-terminus.
We were able to obtain such striking evidence for these long-range interactions because of the existence of isolated dimorphisms at positions 86, 71 and 57 in several DR4 subtypes, and because our PM-A T cell shows unusually broad cross-restrictions to them. As we propose below, they are most simply explained by subtle effects on the conformation of the peptide-DR complex, though definitive proof awaits detailed structural comparisons.
The role of 86 Val ↔ Gly Our findings on both peptide binding and presentation support the importance of this widespread dimorphism noted previously (6, 8, 9, (14) (15) (16) (17) (18) (19) 21) . As the crystal structures for HLA-DR1 and DR4 show (2,3) , the side-chain of 86 Val protrudes into the 'pocket 1' that accommodates the major hydrophobic 'anchor' residue near the N-terminus of the peptide (Fig. 3) and it often hinders the binding of bulkier side-chains there (8, 9, (14) (15) (16) (17) (18) (19) 21, (26) (27) (28) . In the present case, the 149 Trp clearly plays this p1 anchor role; merely changing it to a less bulky Phe (or Leu) consistently and completely overcame this restriction in Dw14.1 (leading to maximal stimulation). Interestingly, that also applied not only to two other T cell clones from Dw14.2 ϩ donors (14) , but also to three further T cells restricted to DR52a/DR3 (27)-which supports the generality of this phenomenon. Notably, in both Dw14.1 and DR3, it was not overcome by a 149 Tyr; presumably its effective bulk is increased by hydration. Unexpectedly, for the sensitive PM-A, the small 149 Ala at p1 allowed significant functional binding of this epitope, especially to Dw4.1, and Dw14.1 (Fig. 2) , presumably because it has a high overall binding score (16, 29) , reflecting multiple interactions along its core (16) (17) (18) 26, 29, 30) .
More surprisingly, the effects of this 86 Gly → Val substitution depended greatly both on the length and potency of the peptide and especially on other substitutions elsewhere in DRβ. As confirmed by site-directed mutagenesis (31), the 71 Arg → Lys replacement in Dw4 is crucial. Thus the 86 Val restriction proved to be less complete-but also less readily overcome-in the context of 71 Lys (in Dw4.1) than of 71 Arg (in Dw14.1). These side-chains clearly point 'sideways' at the peptide (2,3) and the lesser bulk or hydrogen bonding with 71 Lys (see below) evidently enhances binding even of the large 149 Trp or Tyr in pocket 1 in Dw4.1, e.g. by permitting more flexibility in the middle of the peptide. Presumably, similarly permissive changes in DRβ must allow accommodation of the promiscuous HA 307-319 peptide in other alleles with 86 Val (despite its Tyr at p1), even though it generally binds better to those with 86 Gly (18, 19) . Conversely, Krieger et al. (8) were also able to compensate for this 86 Val by substituting smaller residues at p4-6 in the middle of the peptide; they concluded that some changes in its orientation enhanced binding, whereas others had much greater effects on its recognition by T cells (8) , as also noted in mouse class II molecules (32) . Analogous changes in peptide orientation can also result from alterations in the p1 anchor residue itself (22) .
The role of 71 Arg ↔ Lys There is a shallow pocket '4' in the middle of the groove (Fig. 3) ; the polymorphic DRβ residues 70 (above), 71 (below), 74 and 78 contribute to its side wall, and those at 13, 26 and 28 to its floor (2,3). The natural substitutions found here usually have far less effect on peptide binding per se than on the recognition of the bound peptide (8,20,21,33 ), as we have observed both here and in a parallel study (14) . Thus, many T cells are totally dependent on the autologous 71 Lys (14, 21) or 71 Arg (14) , even for recognizing an identical peptide that clearly binds well in both cases. Indeed, only four of 16 published T cells tolerate both 71 Lys and 71 Arg (14, 20, 21, 33) ; when they do, as here with PM-A, this interchange still has major effects, such as the disproportionately greater efficiency of presentation relative to binding by Dw14.1 than by Dw4.2 ( Fig. 2a and b) . Similarly also, presentation of substituents for five of the core residues was drastically reduced in the context of 71 Lys. As these all-or-nothing differences were clearly not caused by better binding by Dw14.1 (which was considerably weaker, Fig. 2b ), they must result from differences in the conformation of the peptide-DR complex (8, 20, 21, 33) . Since they were also greatest at secondary TCR contact sites as far apart as p2, p3 and p8, differences in the peptide seem likely, especially as 71 Arg lies deep to 70 Gln, and therefore contacts the peptide and not the TCR (2, 3) . Although this 71 Lys → Arg substitution appears conservative, Arg sidechains normally form several more hydrogen bonds than Lys (34) ; here at position 71, these create links not only with DRβ 28 Asp in the floor of the groove and with the 70 Gln above (Fig. 3 ), but also with the backbone of the bound peptide (2, 3) . A consequent increase in peptide rigidity in the autologous Dw14.2 might bias heavily in favor of the optimal conformation for PM-A T cells; as a result, not only is presentation disproportionately efficient, but many substitutions along the length of the core are less critical here than in Dw4.2, where the 71 Lys may allow excessive flexibility (Fig. 2) . This may be further enhanced by the 152 Asp → Ala replacement at p4, which is an accessory class II contact site in DR4 (16, 17, 33) .
Interactions between positions 86 and 57
In this most extreme/remote example, neither the 86 Gly ↔ Val (in Dw14.1) nor the 57 Asp → Ser (in Dw15) interchanges alone affected presentation substantially, whereas together (in Dw15.1) they reduced the potency of our best peptides at least 100-fold (Fig. 2c) . That is probably an effect on recognition, which is generally less promiscuous/permissive, but even a loss of binding would still be compelling evidence of an indirect interaction between positions 86 and 57 in Dw15.1, again apparently mediated by the peptide conformation or orientation. The parallel effects with all the analogues suggest some global decrease in the probability of a recognizable conformation in Dw15.1 and so does the requirement for prolonged pulsing at high concentrations (as with Dw13.2) (14) . Moreover, the crystal structure suggests an explanation; the 57 Asp → Ser substitution here prevents formation of the salt bridge that otherwise runs from the carboxyl group of the 57 Asp across to 76 Arg in DRα and lies deep to the peptide (2,3) (Fig. 3) . We propose that this 57 Ser in Dw15.1 alters the conformation of longer peptides at this (C-terminal) end of the groove so that they can no longer be recognized at the other end. In independent support of that, the variant peptides truncated at p10 overcame these effects surprisingly well despite their weak presentation by other subtypes (Table 2) . A theoretical alternative explanation is that there are interactions between adjacent peptide-DR complexes on the APC (35) that are sensitive to alterations in these anchoring pockets, e.g. because of mutual interference by the protruding N-and C-termini of the bound peptide(s).
Sometimes from less clear-out findings, others have also invoked conformational alterations in peptide-class II complexes, whether resulting from differences in the loading process (36) , or in the sequences of the class II molecules (8, 21, 33, 37) or of the peptides presented (8, 32) . As observed in class I (38) and DR4 (3), there may be subtle changes in the α helices as well as in the bound peptide which may have more freedom/flexibility, e.g. because of fortuitous intervening water molecules (3, 38) . Moreover, both the peptide and the helices in class I can apparently adjust on binding of the TCR (39) . While the X-ray crystal structures have so far shown very limited plasticity in the peptide conformation in DR molecules (2,3), even minor changes can have drastic effects on T cell recognition (38) . Furthermore, all the DR structures reported so far are from molecules with 57 Asp, whereas we saw the most extreme and remote effects with 57 Ser (in Dw15.1); its interactions with 86 Val ranged over eight to 10 residues in the (extended) peptide and Ͼ30 residues in the α helix of DRβ. Analogous interactions may well occur with other polymorphic residues in the floor of the groove (33, 37) and/or in the α chain in DQ or DP, though the rarity of isolated dimorphisms there would make them harder to discern than in DR4.
This substantial body of evidence may seem inferential. Nevertheless, working from precisely analogous findings, Krieger et al. (8) correctly predicted not only the extended conformation of HLA-DR-bound peptides and their p1 anchorage via pocket 1, but also the existence of a turn near p5 (2, 3) . Definitive proof of our deductions will require detailed crystallographic comparisons of several peptides in several alleles (not all yet available in homozygous form; Table 1) ; already, however, several structurally established precedents in HLA class I (38-41) lend strong support.
Conclusions
Whatever the final explanation, these unexpected findings must have consequences for epitope prediction/identification and for disease susceptibility as well as for MHC evolution. For example, the effects of individual substitutions in HLA-DR may depend greatly both on the exact length and potency of the peptide and on their context in the rest of the class II molecule. This might become important in vaccine design; e.g. merely by using a more potent peptide, we achieved strong presentation by Dw4.1 as well as Dw4.2, whereas, for Dw14.1, we had to change the p1 anchor too. Therefore one may also need to consider the exact length and sequence of the naturally processed epitope when designing vaccines.
Our findings must be relevant in rheumatoid arthritis, where arthritogenic peptides may be involved (11) (12) (13) (14) 17) , and where there are strong associations with Dw4.2, Dw15.2 and both Dw14.1 and Dw14.2, but not with Dw10.1 or Dw13.2 (11) (12) (13) (14) . These striking differences may reflect the impact of positions 70, 71 and 74 on T cell recognition as well as on peptide binding (13) (14) (15) 17) . Furthermore, our results clearly show that the 70 QRRAA 74 and the 70 QKRAA 74 sequences in DR4β are not functionally equivalent, as was initially assumed in some theories (11) . Indeed, since they largely activate distinct subsets of T cells, those that are cross-restricted to both Dw4 and Dw14 may be highly unusual (14) .
Finally, the importance of the context of particular substitutions in class II may help to explain both the rarity of the 86 Val-57 Ser combination in particular in HLA-DR alleles and their general tendency to evolve by replacements of 'cassettes' of codons rather than by point substitutions. While these often point into the same pocket and contact the same residue in the peptide (1-3), they are sometimes more dispersed, as, for example, in DR12 (1); this allele has distinctive residues in both pockets 4 and 9, perhaps to favor long-range interactions such as those described here. In either case, they must serve to increase the diversity of peptide-MHC conformations presented to specific T cells, and thus broaden the range of epitopes and pathogens that can be recognized.
